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Abstract:
Background of the study:
                           IgA nephropathy is the most common Glomerulonephritis in almost all 
parts of the world. It is unique among Glomerular diseases is being defined by 
immunohistochemical findings of Mesangial deposition of IgA. New OXFORD MEST 
scoring system introduced in 2010 uses four variables that predict the renal outcome
accurately. These four variables are 1. Mesangial hypercellularity, 2. Endocapillary 
proliferation, 3. Segmental sclerosis and 4. Tubular atrophy.
Aim of the study:
                        To assess the Prognosis of IgA Nephropathy by NEW OXFORD MEST 
scoring system and to analyze other clinical, biochemical  and histological factors in 
predicting the renal outcome. 
Materials and Methods:
            Renal case records of Department of Nephrology, Kilpauk Medical College from 
June 2008 to December 2010 were searched. Case records of Patients with renal biopsy 
finding of IgA nephropathy were included in this study.
NEW OXFORD MEST scoring system was applied and the severity of renal 
lesion at the time presentation was analyzed. The contribution of the Mean Arterial 
Pressure, baseline Serum Creatinine, Creatinine Clearance, Proteinuria, serum Uric Acid 
and serum Triglycerides in predicting the high Total MEST score was analyzed. Clinical, 
Biochemical and Histopahtological factors other than MEST score in predicting the 
progression of the disease were also analyzed.
Results:
A total of 44 patients, 25 patients were males. Mean age group was 31 to 50 yrs of 
age (52.7%). Mean period of follow up was 17.2 months. Macroscopic hematuria was 
found in 11 patients (22%). Microscopic hematuria was found in all patients (100%). 
Systemic hypertension was found in all patients (100%). Nephrotic proteinuria was found 
in 12 patients (27.3%). Mean urine spot protein creatinine ratio of patients 2.61 gm per 
gm of creatinine. Mean serum creatinine of the patients was 2.06mg/dl. Mean creatinine 
clearance of Non Progressors and Progressors was 59.6ml/min and 28.63ml/min 
respectively. Mean total MEST score of Non Progressors and Progressors was 2.12 and 
3.16 respectively. Disease progressed in 19 patients (43.1%) and more in males(58%). 
Disease progressed more in younger age group(15to30 yrs -63.15%).
Conclusion:
                 High Total MEST score at the time of presentation is an individual predictor of 
Disease Outcome. MEST score is neither superior nor inferior in predicting the Renal 
Outcome when compared to Creatinine Clearance and Nephrotic proteinuria.
Key words : IgA nephropathy, New Oxford MEST score.                     
Introduction :
IgA nephropathy is the most common Glomerulonephritis in almost all
parts of the world where the renal biopsy is widely practiced1a. It is unique
among Glomerular diseases is being defined by immunohistochemical findings
of Mesangial deposition of IgA.
Diseases associated with glomerular IgA deposition can be divided into
primary and secondary. Primary IgA nephropathy is an immune complex
mediated glomerulonephritis. Diseases associated with primary causes are IgA
nephropathy and Schonlein- Henoch Purpura.
IgA nephropathy is a renal limited disease, having a varied histological
presentation. Histologically IgA nephropathy varies from Minimal lesion to
diffuse proliferative glomerulonephritis.Focal mesangial proliferative
glomerulonephritis is the most common presentation.
Schonlein- Henoch Purpura is distinguishable from primary IgA
nephropathy by its dominant systemic manifestation in younger individuals.
Dominant clinical features are Leukocytoclastic vasculitic lesion in lower
limbs, abdominal pain, arthritis and renal involvement in the form of
proteinuria and renal failure. Focal and diffuse glomerulonephritis with
crescents are the dominant renal biopsy features.
Secondary causes of IgA deposits in mesangium are
1. Diseases of the liver: alcoholic, primary biliary, or cryptogenic cirrhosis;
hepatitis B (where endemic);chronic schistosomiasis
2. Diseases of the intestine: Celiac disease; Chronic ulcerative colitis;
Crohn’s disease
3. Diseases of the skin: Dermatitis herpetiformis; Psoriasis
4. Diseases of the bronchus or lung: Sarcoidosis, Idiopathic pulmonary
hemosiderosis; Cystic fibrosis;Bronchiolitis obliterans
5. Neoplasia: Carcinoma of the lung, larynx, and pancreas; Mycosis
fungoides
6. Infection: Human immunodeficiency virus; Leprosy
7. Other systemic or immunologic disorders: Systemic Lupus
Erythematosus; Rheumatoid arthritis; Cryoimmunoglobulinemia;
8. Psoriatic arthritis; Ankylosing spondylitis; Sjögren’s syndrome;
Behçet’s syndrome;
9. Reiter’s syndrome; Familial immune Thrombocytopenia; Autoantibody-
mediated (monoclonalIgA–mediated) Goodpasture’s syndrome
10.Diseases coincident with IgA nephropathy: AntiNeutrophilic
Cytoplasmic Antibody–associated vasculitis;Diabetic nephropathy;
Membranous Nephropathy;  Granulomatous polyangitis
New Oxford MEST scoring system60 is a newly emerging scoring
system for IgA nephropathy that predicts the prognosis accurately. This scoring
system consists of Mesangial hypercellularity, Endocapillary proliferation,
Segmental sclerosis and Tubular atrophy.
Review of literature :
IgA nephropathy first became recognized as a distinct entity in 1968 by
Berger and Hinglais from a cohort of patients with persistent Microscopic
Hematuria, episodes of macroscopic Hematuria that were often associated with
sore throat. Mild to moderate Proteinuria without Nephrotic syndrome and
Normal renal function is the most common presentation1. Renal biopsies from
these patients showed varying histological features ranging from normal to
chronic glomerulonephritis, but most often focal glomerulonephritis, without
typical features of acute post infectious glomerulonephritis.
Immunoflourescence microscopy in each case showed mesangial deposition of
IgA usually accompanied by less intense staining of IgG and C3. Electron
microscopy confirmed the presence of mesangial immune complex deposits2.
Incidence and prevalence of IgA nephropathy- world scenario:
IgA nephropathy is recognized as the most common form of primary
glomerulonephritis in the world. Incidence and prevalence of IgA nephropathy
in general population shows a considerable variation among geographical
regions. The reported incidence in three regions in France and one each in the
Netherlands, Germany and Italy varied from 15 to 40 new cases per million
populations per year3-7. The incidence is higher in Japan, where routine
screening for urinary abnormalities is performed in all school-agedchildren. 48
percent of Japanese children initially identified through urinary screening
program who subsequently underwent a renal biopsy had IgA nephropathy8.
Incidence of IgA nephropathy was, 45 new cases/100000 population in Japan,
43  per million populationin France  , 10  per million population in USA , 6 per
million populationNew Zealand (white)  and  2 per million population in New
Zealand( polynesian).
Prevalence appears highest in Asia (Singapore, Japan, andHong
Kong).Prevalence in Australia, Finland, and southern Europeis reported to be
20 to 40 percent. In the United States prevalence rates of IgA Nephropathy was
as low as 2 to 10 percent9. In Native Americans from New Mexico, the
prevalence rate was 38 percent9.  In a recent study of renal allografts in Japan
revealed mesangial IgA deposition in 19 %( 82 out of 510) and 19 of those had
mesangial proliferation10.
Incidence and prevalence- Indian scenario: - An increasing trend:
Available evidence suggests an increasing incidence in India. In 1987, a
frequency of 4.2% was reported from Tamil Nadu11. In 1992, a frequency of
7.24% was reported from New Delhi12 and in 1995, 10.37% was reported from
the Union Territory of Chandigarh13. In retrospective study of IgA nephropathy
from Kerala, out of 1592 renal biopsies, 227 cases were diagnosed as IgA
nephropathy (14.26%). Of these, 85 out of 677 were in the first year (12.74%)
and 142 out of 915 in the second year (15.52%) suggesting an increase in
incidence18.
Demography:
Primary IgA nephropathy occurs at any age, most commonly with
clinical onset in the second and third decades of life14.There is a Male: Female
ratio ranging from less than 2:1 in Japan to as high as 6:1 in Northern Europe
and the United States15. Whites and Asians are more prone to IgA nephropathy
than are Blacks from the United States and from South Africa16, 17.
Pathogenesis:
The main hypothesis indicates that the development of the IgA
nephropathy can be divided into three main stages: I) IgA deposit in the
mesangium; II) generation of the mesangial lesion mediated by the interaction
of the IgA1 complexes with specific receptors or through the activation of the
complement, and III) progression of the mesangial IgA lesion towards chronic
renal failure19. IgA Nephropathy is an immune complex glomerulonephritis
that involves intense deposition of dimeric and polymeric forms of IgA1 within
the mesangium of the glomerulus24.
Stage 1: Deposition of IgA:
Fundamental to immune complex formation (IgA- IC formation) is
excessive production of poorly O galactoylated IgA1 found in serum, however
the presence of these excessive IgA1 O glycoforms alone is insufficient to
cause IgA Nephropathy and a second hit is required for deposition in
mesangium20. In this second hit, glycan specific IgG and IgA antibodies formed
and recognizes the poorly O galactosylated IgA 1 in the serum. Genetic factors
heavily influence the level of poorly O galactosylated IgA1 in the serum and
they alsoinfluence the autoantibody formation in IgAN21-23.
The two-hit hypothesis for IgA-IC formation in IgAN
IgA molecule:
IgA molecule is a major immunoglobulin in mucosal secretions but is
present in relatively low concentrations in serum. Its predominant function is in
mucosal defense. Two subclasses of IgA exist in humans, IgA1 and IgA2, both
of which occur in Monomeric (mIgA) and Polymeric (pIgA) forms.  90 % of
Serum IgA is Monomeric whereas that found in mucosal secretion is
Polymeric.  IgA1 accounts for 90% of serum IgA, produced in bone marrow,
lymph nodes, plasma cells and spleen. IgA2 comprises 60% in mucosal areas.
Polymeric IgA contains the bridging or joining polypeptide – j chain- linked to
the heavy chain during the formation of multimers within the plasma cell.
IgA1 possess an 18 amino acid in the hinge region between CH1 and
CH2 domains of heavy chain.  This is absent in IgA2 molecule. Hinge region
consists of repeating sequence of proline, serine and threonine residues and
carries multiple O linked carbohydrate side chains connected to serine and
threonines. This O linked sugars of IgA1 molecule increase the size
significantly and confers a high negative charge because of sialylation of
sugars.
Galactosylation defect:
Under normal conditions, IgA1 molecules are glycosylated by the union
of Nacetyl galactosamine (GalNAc) to the hinge region and forms Serine or
Threonine/GalNAc complex, through the action of the beta-1,3 galactosyl
transferase enzyme and  forms the Gal-GalNAc disaccharide. And in this
complex through the action of the alpha-2, 3 sialyltransferase enzyme, can
incorporate one or two units of sialic acid.25, 26. This is called sialylation.
IgA nephropathy patients present with glycosylation deficiency
(hypoglycosylation) in hinge region. The immortalised B-cells of patients with
IgA nephropathy produce galactosylation deficient IgA27. These cells present
with reduced activity of beta-1, 3 galactosyl transferase and its chaperone
(COSMC).But the Mutations in the genes of the beta-1, 3 galactosyl transferase
(C1 GALT1) and COSMC are inconclusive. Premature sialylation of the IgA,
as a consequence of an increase in the alpha-2,3sialyltransferase activity, could
block the process of galactose incorporation. There is evidence that both the
alpha-2, 6 sialyl transferase as well as the expression of its ST6 GALNA C2
gene is altered in the IgA nephropathy28-31. These mutations prove that the
glycosylation defect is hereditary32.
The IgA1 molecule showing the position of the hinge region O-glycans and the major
O-glycan forms found in human IgA1. (A) The hinge region of IgA1 lies between the CH1
and CH2 domains of the _1 heavy chain. The hinge region is made up of 17 amino acids. (B)
Serineand threonine residues provide nine potential O-linked glycosylation sites (arrows);
although to date only six are known to be occupied by O-glycans. It is still not known which
amino acids are occupied by O-glycans and whether it is the same amino acids for all O-
glycoforms of IgA1. (C) The IgA1 O-glycans are all based on a core 1 structure with GalNAc
units in O-linkage with serine or threonine. This may occur alone (form I) or may be extended
with either sialic acid in _2,6-linkage with GalNAc (form II) or _1,3-linked galactose (form
III). Further extension with sialic acid in _2,3-linkage with galactose also can occur (form
IV).
Aggregation of hypoglycosylated IgA;
The hypoglycosylated IgA1 has the capacity of self-aggregationand
forms polymeric aggregates with other IgA1 molecules. The IgA1 polymers
formed by self-aggregation, after interacting with the Fc alpha receptor on the
surfaces of the lymphoid and mononuclear cells, can break its extracellular
component and give rise to soluble polymeric IgA RR Fc alpha complexes that
are deposited in the mesangium. The hypoglycosylated region of the hinge
exposes immunogens that generate the production ofcirculating IgG antibodies,
giving rise to immune complexes IgA1 polymeric-IgG. This macromolecular
and immune complex persists in the circulation. They cannot be recognized by
the hepatic Asialoglycoprotein receptors and are deposited in the renal
mesangium due to their affinity to extracellular matrix proteins or through the
interaction with specific mesangial receptors.
Polymeric IgA interaction with specific mesangial receptors
Transferrin TFR or CD71 receptor is expressed very little in quiescent
mesangial cells, but it is found over expressed in IgA nephropathy patients33.
CD71 is able to bind polymeric IgA1, but not monomeric IgA1, and several
experimental data have shown that the polymeric IgA1-CD71 union causes an
activation of the mesangial cell, which results in proliferation and production
IL-6, TGF beta and other cytokines.
Activation of complement:
The polymeric IgA1 is able to activate the alternative route of the
complement34.  In some patients, polymeric IgA co-localizes with MBL and
can activate the complement through the lectin route35.
Stage II
Generation of mesangial lesion:
Mesangial cells preferentially bind to poorly O galactosylated IgA1
principally through the transferring receptor (CD71), triggers mesangial cell
proliferation and apoptosis, reduced synthesis of vascular endothelial growth
factor, altered integrin expression, and increased synthesis of extracellular
matrix components36.
Secretory component of IgA, with a high sialic acid content and its
anionic property stimulates mesangial cells resulting in activation of the
p42/p44 mitogen activated protein kinase, activator protein-1, and NF-Bsignal
transduction pathways along with up-regulation of IL-6, transforming growth
factor-β (TGF-β), tumor necrosis factor (TNF-α), monocyte chemoattractant
protein1 (MCP-1), IL-8, and macrophage migration inhibitory Factor37.
Podocyte injury:
Necrosis and detachment of podocytes from the GBM has been reported
in IgA Nephropathy and the degree of podocytopenia is closely related to the
increasing severity of glomerular lesions38.Nephrin mRNA and extracellular
nephrin expression are reduced in IgA Nephropathy, particularly in patients
with heavy proteinuria39. Podocytes can bind IgA-IC but in a much lower
affinity than mesangial cells.  Podocytes do not express transferrin receptor but
they may express another novel IgA Receptor and it is widely accepted that
mesangial cells also express an undefined receptors for IgA40. Exposure to IgA-
IC results in down-regulation of nephrin expression. Down-regulation of
nephrin is likely to lead to structural and functional changes in podocytes
manifest principally by foot process effacement and increased glomerular
permeability.
Stage III. Progression of the mesangial IgA lesion towards chronic renal
failure –tubulointerstitial scarring:
Until recently been thought that the mechanisms of subsequent
tubulointerstitial injury were generic and common to all forms of chronic
kidney disease. Recent work suggests that there may be direct and specific
pathogenic interactions between filtered IgA-IC, mesangial cell– derived
mediators, and proximal tubule epithelial cells (PTEC) 41. PTEC are constantly
exposed to filtered IgA-IC once the glomerular size barrier is impaired. PTEC
can bind IgA with lower affinity than mesangial cells. There is some evidence
that this binding is greater for IgA isolated from patients with IgAN42.PTEC do
express the transferrin receptor. There has been a single report of tubular
expression of a novel polymeric immunoglobulin receptor, the Fcα/µ
receptor43.This receptor binds both IgA and IgM and appears to be expressed
exclusively by tubular epithelium, with no expression within glomeruli43.
Mesangial cell– derived mediators have been shown to activate extracellular
signal-regulated kinase and NF-_B signaling pathways, up-regulate IL-6,TNF-
α, migration inhibitory factor, and intercellular adhesion molecule 1
expression, and alter expression of both the type 1 and type 2 angiotensin II
receptors in PTEC44. Potential factors mediating this Glomerulo tubular cross-
talk include angiotensin II, IL-1, IL-6, TNF-α, MCP-1, TGF-β, and platelet-
derived growth factor. PTEC activation by mesangial cell– derived mediators
appears to be influenced heavily by intracellular levels of the ligand-activated
transcription factor PPAR-ϒ45.
Clinical features:
Pattern of clinical presentation:
Common:
1. Synpharyngitic macroscopic hematuria+/- loin pain
2. Microscopic hematuria
3. Hypertension
4. Chronic Kidney Disease
5. Henoch schonlein Purpura
Uncommon:
1. Malignant Hypertension
2. Acute Nephritic Syndrome
3. Acute renal failure
4. Nephrotic syndrome
Macroscopic Hematuria:
The most dramatic presentation is episodic macroscopic hematuria in
young adults. Approximately 40 to 50 percent of the patient presented with
macroscopic hematuria. Hematuria has a characteristic temporal association
with upper respiratory tract infection. Hematuria usually coincides with or
occurring within 1 to2 days of the sore throat.  Hematuria is usually painless
but often associated with systemic symptoms such as fever, malaise, fatigue,
diffuse muscle aches and dull loin pain. Macroscopic hematuria occurs more
frequently in children and young adults than in middle or elderly patients. This
feature is virtually never seen after the age of 40 yrs.
Asymptomatic Hematuria:
Approximately 30 to 50 percent of the IgA nephropathy patients are
incidentally discovered by microscopic hematuria. This occurs at any age but it
is typical in older patients. There is an iceberg effect in the prevalence of this
presentation.
Proteinuria and Nephrotic syndrome:
Proteinuria in the absence of hematuria is an uncommon presentation.
Nephrotic range proteinuria is also uncommon, but can occur in the presence of
very active disease or advanced disease with considerable scarring. The
presentation is only 5 percent of all IgA nehropathy.
Hypertension and Malignant hypertension:
An important proportion of patients with IgA nephropathy are detected
during investigation of newly diagnosed hypertension. It is one of the major
causes of hypertension in young adults. Malignant Hypertension is the one of
the most dramatic presentation in IgA nephropathy.
Acute renal Failure:
ARF is an uncommon feature in de novo IgA nephropathy, occurring in
only 5 percent of the patient. It may occur during episodes of Macroscopic
Hematuria, possibly as a result of tubular obstruction by red blood cells.
Rapidly progressive renal failure:
This usually occurs as a result of acute necrotizing, Crescentic
glomerular injury. It is a strongest indicator of aggressive immunosuppressive
therapy. It is an analogous to pauci immune crescentic glomerulonephrits46.
There are number of cases that seem to be associated with IgA  ANCA, but
overall findings are inconsistent. A few patients had linear capillary wall IgA
deposition, presumably an IgA variant of Good Pasture syndrome47.
Chronic Renal Failure;
Approximately 10 to 20 percent of patients with IgA nephropathy had
chronic established renal failure at presentation. This fact is clouded by late
attention in the course of renal disease; since many do not have a renal biopsy.
Undoubtedly many of those with end stage or near end stage renal disease with
small kidneys had unrecognized IgA nephropathy for years or decades. The
lack of a reliable peripheral diagnostic marker of IgA nephropathy is an
obvious deficit.
Histopathological features and classification of IgA nephropathy:
The first histological lesions that appear in the glomeruli are increased
extra cellular matrix and hypercellularity of the mesangium. Subsequently, the
spectrum of glomerular abnormalities may enlarge and virtually all
morphological manifestations of glomerular abnormalities such as floculo
capsular adhesions, segmental sclerosis and crescents may be observed. For
this reason different classification systems have been introduced.
Earlier classification system:
Lee SM et al48 in 1982 evaluated the clinical and pathologic findings of
20 unselected patients with IgA nephropathy. 13 patients were followed for 1.5
to 5 years (mean 2.8 years).The activity and severity of the lesions were graded
according to a modified classification used by Meadow et al. for the
nephropathy associated with Henoch-Schönlein Purpura49. The results reveal a
correlation between the histopathologic grading in the initial biopsy and the
clinical outcome: Patients with mild (grade II) or moderate (grade III) lesions
had a benign course or showed evidence of active disease without deterioration
of renal function, whereas all patients with grade IV or V lesions who were
followed for more than one year developed end-stage renal failure. These
observations suggest that histologic grading at initial renal biopsy may be a
useful prognostic indicator of the clinical outcome of IgA nephropathy.
Histological Classification of IgA Nephropathy of LEE et al
Histological
Grade
Glomerular changes Tubular and
Interstitial changes
I Mostly normal occasional slight
mesangial thickening with or without
hypercellularity
Absent
II Less than 50% of glomeruli show
localized mesangial proliferation and
sclerosis, rarely small crescents
Absent
III Diffuse mesangial proliferation with
focal and segmental variation
occasional small crescents
Focal interstitial
edema and infiltrate
,tubular atrophy rare
IV Marked diffuse mesangial
proliferation and sclerosis, crescents
<45% of glomeruli
Tubular atrophy,
interstitial
inflammation and
occasional interstitial
foam cells
V Similar to IV but more severe
crescents in > 45% of glomeruli
Similar to IV but more
severe
Lee SM, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Spargo BH, Katz AI: IgA
nephropathy: Morphologic predictors of progressive renal disease. Hum Pathol13: 314–322,
1982
Mark Hass et al in 1997 published the histologic features of 244 cases of
IgAN (not including Schlinlein-Henoch nephritis) diagnosed between 1980 and
1994 and was subclassified using the following, relatively simple histologic
classification schema50:
Histologic Subclasses of IgA Nephropathy: Definitions
Subclass I
Minimal histologic lesion
The glomeruli show no more than a minimal increase in mesangial
cellularity, without segmental sclerosis or crescents.
Subclass II
Focal-segmental glomerulosclerosis-like
The glomeruli show focal and segmental sclerosis in a pattern resembling
primary focal-segmental glomerulosclerosis, with at most a minimal increase
in mesangial cellularity, and no crescents
Subclass III
Focal proliferative GN
Fifty percent or fewer of the glomeruli are hypercellular. The increase in
cellularity may be limited to mesangial areas, or there may be obstruction of
glomerular capillaries by proliferated endocapillary cells. Crescents may be
present. While the great majority of subclass Ill lesions show segmental
glomerular hypercellularity, this is not a requisite for assigning a biopsy
specimen to this subclass
Subclass IV
Diffuse proliferative GN
More than 50% of the glomeruli are hypercellular. As with subclass Ill, the
hypercellularity may be segmental or global, and crescents may be present.
Subclass V
Advanced chronic GN
Forty percent or more of the glomeruli are globally sclerotic, and/or there is
240% tubular atrophy or loss in the cortex as estimated from periodic acid-
Schiff-stained sections, If these features are present, the biopsy specimen is
assigned to subclass V regardless of other  histologic features.
Hass et al borrowed the features from Lee et al, WHO Lupus Nephritis
classifications and from D’Amico et al51 with respect to multiple individual
renal survival in a large cohort of Italian IgA nephropathy patients.
Mark Hass  et al50, find the statistically significant correlation between
histologic subclass and renal survival, with an order I, II (greatest survival) >
Ill> IV, V. Crescents were a significant negative prognostic indicator for renal
survival in subclass Ill (but not in subclass IV), and interstitial expansion was a
negative prognostic indicator in subclasses Ill and IV, although the statistical
significance of these were not maintained after controlling for serum creatinine
at the time of biopsy. The presence of peripheral glomerular capillary deposits
ultrastructurally had no prognostic significance. With respect to clinical
presentation, hypertension and proteinuria of >2.0 g/24 hour were significant
negative prognostic indicators for renal survival, even when controlling for
serum creatinine at the time of renal biopsy. The presence of gross hematuria
correlated significantly with increased renal survival by univariate analysis, but
was not correlated when controlled for serum creatinine at the time of renal
biopsy. The findings of this study confirm the wide variety of clinical and
histopathologic presentations of IgAN, and indicate the utility of the proposed
histologic classification schema in assessing a patient’s likelihood of ultimately
developing end-stage renal disease.
These earlier classification systems divide the group into Lumped and
Split. Lumped system was introduced by Lee et al48 and mina and Murphy et
al52. Split system was used by Kobayashi et al53 (1983), Andreoli and Bergstein
et al54 (1989),Alamartime et al55 (1990) and Waldo  et al 56 (1993). Lumped
system is used for its simplicity and easy application in large multicentre
studies. This scoring system as mild, moderate and severe is valuable in the
analysis of a large clinical database. The weakness of the lumped system is the
lack of flexibility in interpretation and important pathological changes are
missed. The lumped system is more useful for diagnosis and grading of IgA
nephropathy. The Split system gives the detailed analysis of each lesion by
introducing a global score which provides the information on glomeruli,
tubules, interstitium and vessels. This system has more flexibility and minimal
intercentre variability.  The Split system gives more information regarding the
progression of the disease.
Classification system by Chrug and Sobin57 (1982) was accepted by
World Health Organisation and recently updated58 (1995) and revised (2000).
This scoring system was slightly modified from Pirani and Salinas –Marrigal59
classification (1968).This grading system is based on the severity of cellular
proliferation and glomerulosclerosis, number of crescents and presence and
absence of tubular atrophy and interstitial cellular infiltration or fibrosis. This
classification system divides the lesion into three grades: G1 mild includes
patients with minor or minimal lesions, G2 moderate includes patients with
focal-segmental or diffuse proliferative glomerulonephrits, G3 severe includes
patients with sclerotic lesions in advance chronic glomerulonephritis or end
stage renal disease.
Histological classification of IgA nephropathy, Chrug and Sobin. Accepted by
WHO(1995)
Grade class Glomerular changes Tubulo interstitial changes
I A Normal glomeruli
B Slight mesangial hypercellularity
C Slight mesangial matrix expansion
II A <25% of the glomeruli with
moderate focal and segmental
mesangial proliferation and rare
sclerosis. Rare crescents
Occasional focal interstitial
infiltrate
B Up to 50% of the glomeruli with
moderate focal and segmental
mesangial proliferation and
sclerosis. Capillary obstruction by
endocapillary cell proliferation.
Adhesions and cellular crescents
less than 25% of glomeruli
Focal infiltrate less than
25% of cortical area
C >50% of the glomeruli with
segmental proliferation and
sclerosis. Adhesions and cellular
crescents up to 50% of glomeruli
Tubular atrophy and
interstitial infiltrate up to
50% of the cortical area.
III A <25% of the glomeruli with focal
and segmental or global sclerosis.
Adhesions and fibrous crescents less
than 25% of glomeruli.
Tubular atrophy, interstitial
infiltrate and sclerosis in less
than 25% of the cortical
area.
B Sclerosis up to 50% of glomeruli.
Adhesions and fibrous crescents up
to 50%of glomeruli.
Tubular atrophy, interstitial
infiltrate and sclerosis up to
50% of the cortical area
C Sclerosis more than 50% of
glomeruli. Adhesions and fibrous
crescents in more than 50% of the
glomeruli
Tubular atrophy. Interstitial
infiltrate and sclerosis more
than 50% of the cortical
area.
New oxford MEST scoring system:
A Working Group of the International IgA Nephropathy Network and
the Renal Pathology Society headed by Daniel C. Cattran, Rosanna Coppo, H.
Terence Cook, Ian S.D. Roberts, John Feehally introduced this new scoring
system60.The Goal of this new system was to identify specific pathological
features that more accurately predict risk of progression of renal disease in IgA
nephropathy. In this retrospective analysis sequential clinical data were
obtained on 265 adults and children with IgA nephropathy who were followed
for a median of 5 years. Renal biopsies from all patients were scored by
pathologists blinded to the clinical data. Four variables: (1) the mesangial
hypercellularity, (2) segmental glomerulosclerosis, (3) endocapillary
hypercellularity, and (4) tubular atrophy/interstitial fibrosis were analyzed for
their independency in predicting renal outcome. The value of crescents was not
addressed due to their low prevalence in the enrolled cohort.
Recommended elements in renal biopsy repot for a case of IgA
nephropathy:
Detailed description of the features present on
Light microscopy, immunohistochemistry, Electron microscopy
Summary of Four key pathological features
Mesangial score <0.5(M0) or >0.5(M1)
Segmental sclerosis absent (S0) or present (s1)
Endocapillary hypercelluarity absent (E0) or present (E1)
Tubular atrophy/Interstitial fibrosis <25 %( T0), 25-50 %( T1) or
>50%(T2)
Total number of glomeruli with endocapillary hypercellularity,
extracapillary hypercellularity, global glomerulosclerosis,and segmental
glomerulosclerosis
Definitions of pathological variables used in the New  oxford MEST
classification of  IgA nephropathy
Variable Definition Score
Mesangial
Hypercellularity
<4 mesangial cells/mesangial area=0
4-5 mesangial cells/mesangial area=1
6-7 mesangial area/mesangial area=2
>8mesangial area/mesangial area=3
Mo <0.5
M1 >0.5
Mesangialhypercellulrity score is the mean score for all glomeruli
Segmental
glomerulosclerosis
Any amount of the tuft involved in
sclerosis, but not involving the
whole tuft or the presence of an
adhesion
S0-absent
S1 –present
Endocapillary
hypercellularity
Hypercellularity due to increased
number of cells within glomerular
capillary lumina causing
narrowing of the lumina
E0- absent
E1 – present
Tubular atrophy/
Interstitial fibrosis
Percentage of cortical area
involved by the tubular atrophy or
interstitial fibrosis, whichever is
greater
0 -25% -T0
26-50% -T1
> 50% –T2
Reproducibility of pathology variables:
A Working Group of the International IgA Nephropathy Network and
the Renal Pathology Society headed by Ian S.D. Roberts validated the
Reproducibility of pathology variables61.
Along with the scoring systems using the four variables, mesangial
hypercellularity, segmental glomerulosclerosis, endocapillary proliferation and
Percentage of Tubular atrophy/Interstitial Fibrosis, additionally the cellular/
fibro cellular crescents and arteriolar lesion are also scored.
Extra capillary scoring was done by multiplication factor of 1 was
applied for lesions <10% of the glomerular circumference, factor of 2 for
lesions 10–25% of the glomerular circumference, factor of 3 for lesions 26–
50% of the glomerular circumference, and factor of 4 for lesions 45% of the
glomerular circumference. The resulting scores were summed and divided by
the total number of glomeruli in the biopsy.
For most histological variables, the median score was taken for analysis.
Reproducibility was assessed statistically using Intraclass correlation
coefficients(ICCs). On the basis of the ICC scores, lesions were divided into
three groups as follows
Group 1: Those lesions showing good or very good reproducibility
(>0.6) were mesangial cellularity score, percentage of global
glomerulosclerosis, percentage of cellular fibrocellular crescents, cellular/
fibrocellular crescent score (including adjustment for size of crescent),tubular
atrophy, interstitial fibrosis, interstitial inflammation1, and arterial scores 1, 2,
and 3.
Group 2: Those lesions showing moderate reproducibility (0.4–0.6)
were extent of segmental glomerulosclerosis and percentage of glomeruli
showing either segmental or globalendocapillary hypercellularity.
Group 3: Those lesions showing poor or fair reproducibility (<0.4) were
percentage of normal glomeruli, presence of adhesions, percentage of
glomeruli showing segmental endocapillary hypercellularity, presence of
glomerular basement membrane duplication, presence of necrosis, percentage
of glomeruli showing fibrous crescents, interstitial inflammation (inflammation
involving non-fibrotic cortex), and arteriolar hyalinosis.
The pathological variables that continued to show poor reproducibility
(group 3) within the working group were not incorporated into final
classification.
Finally the following six pathological variables showed good
reproducibility in subsequent analysis, 1.Mesangial hypercellularity score:
percentage of glomeruli showing, 2.segmental glomerulosclerosis,
3.endocapillary proliferation, 4. Cellular / fibro celluar crescents, 5. Percentage
of Tubular atrophy/Interstitial Fibrosis and 6. Arterrosclerosis score, was taken
for extended pathology dataset.
Validation of Oxford Classification of IgA nephropathy:
Andrew M. Herzenberg, Agnes B. Fogo, Division of Nephrology,
Toronto General Hospital, University of Toronto, Ontario, Canada, validated
the Oxford classification of IgA nephropathy using an independent cohort of
187 adults and children with IgA Nephropathy from 4 centers in North
America62. The cohorts had similar clinical and histological findings,
presentations, and clinicopathological correlations with Oxford cohort. Three
of the four pathological variables identified in the Oxford derivation cohort
predicted a rapid rate of renal-function decline in the NA validation data set,
supporting the original findings. In comparison with the Oxford cohort, an
interaction between the E-score and the use of immunosuppressive therapy and
the rate of renal-function decline was validated. This illustrates the potential
role of renal biopsy findings in the selection of IgA patients requiring
aggressive therapy. During follow-up, however, the North American cohort
received more immunosuppressive and anti hypertensive therapies than oxford
cohort.
Natural history of IgA nephropathy:
There is a marked variability in clinical outcome of primary IgA
nephropathy, with a spectrum ranging from complete disappearance of blood
and protein in the urine to the development of chronic renal failure.
Microhematuria disappears spontaneously in 3 to 25 % of the patients. The
overall clinical outcome shows that 60-80 percent of patients continue to have
normal renal function for a mean follow up 2 – 5 yrs63. Renal biopsies from
these patients usually reveal no change or only minimal glomerular lesion.
Stable renal function is generally present in mild form of mesangial
proliferation. Patients with normal or stable renal function have mild
proteinuria, normal blood pressure, and mild histological lesion. A small
proportion patient with macro hematuria, loin pain and normal serum creatinine
rapidly progress to end stage renal disease in 2 to 3 yrs. In these cases the renal
lesions are characterized by crescents and progressive loss of renal structure in
glomeruli.
Patients with Cresentic IgA nephropathy have an increased prevalence
of hypertension, renal insufficiency and nephrotic range proteinuria. Patients
with proteinuria of more than 3.5 gm /day and impaired renal function develop
chronic renal insufficiency within a short period of appearance of clinical
symptoms. A few patients have a very rapid course and terminates in renal
failure are referred as malignant IgA nephropathy.
Prevalence of chronic renal insufficiency appears to be greater in
Australian (23 %) and European (23 %) than in patients from Asia (13 %) and
North America (15 %). The renal impairment is more common in males. Hogg
et al64 (1994) found observed 15 percent of the patients developed end stage
renal disease for a mean follow up period of 4 yrs. Seven variables were found
predictive of end stage renal disease, 1.presence of glomerular sclerotic
changes in more than 20 percent of glomeruli, 2. Afro American race, 3 .Male
gender, 4.Hypertension at biopsy, 5. Proteinuria at biopsy  6.older age at
presentation and 6. Presence of crescents in renal biopsy.
Aim of the study:
1. To assess the Prognosis of IgA Nephropathy by NEW OXFORD MEST
scoring system.
2. To assess the role of Clinical, Biochemical and Histo pathological
parameters other than MEST score (Crescents, Arteriolar Hyaline, and
Blood Vessel Thickening) in predicting the Renal Outcome.
3. To assess the correlation of baseline Mean Arterial Pressure, Serum
Creatinine, Glomerular Filtration Rate and Proteinuria with MEST score
4. To assess whether the MEST score is superior in predicting the Renal
Outcome when compared to baseline Mean Arterial Pressure, Serum
Creatinine, Creatinine Clearance and Proteinuria.
Materials and study protocols:
This is a Retrospective cohort study, done at Kilpauk Medical College
Nephrology department. This study protocol was approved by the Ethical
committee for research studies of Government Kilpauk Medical College
Hospital, Chennai.
Renal case records of Department of Nephrology, Kilpauk Medical
College from June 2008 to December 2010 were searched. Case records of
Patients with renal biopsy finding of IgA nephropathy were included in this
study.
Renal case records were thoroughly searched  for clinical presentation
(age, SHT, Diabetes mellitus, fever with throat pain, macroscopic hematuria,
pedal edema, oliguria, loin pain, blood pressure  and anthropometric
measurements), urinalysis (urine protein, RBC’s and RBC cast in urine, urine
spot protein creatinine ratio (PCR), and urine culture and sensitivity, blood
biochemistry (blood sugar, urea, serum creatinine, serum sodium, serum
potassium , serum uric acid, total proteins, albumin, globulin and serum lipid
profile) histopathological report  of renal biopsy ( both light microscopy and
immunofluorescence microscopy results) and follow up investigations  and
treatment modalities.
Creatinine clearance was calculated with Cockgrauft Gault Formula.
The patients were divided into groups according to the serum creatinine at the
time of presentation. The group of patients according to serum creatinine were;
group I <1.0mg/dl, group II 1.1 to 1.5 mg/dl and group III >1.6 mg/dl.
By applying the NEW OXFORD MEST scoring to each group (group
divided according to the serum creatinine level) separately the severity of renal
lesion at the time presentation was analyzed. MEST scoring system consists of
Mesangial hypercelluarity, Endocapillary proliferation, Segmental sclerosis and
Tubular atrophy. The contribution of the Mean Arterial Pressure, baseline
Serum Creatinine, Creatinine Clearance, Proteinuria, serum Uric Acid and
serum Triglycerides in predicting the high Total MEST score (score of 3 and
above) was analyzed. Clinical, Biochemical and Histopahtological factors other
than MEST score in predicting the progression of the disease were
alsoanalyzed.
Follow up Serum creatinine, urine RBC and urine spot Protein
Creatinine Ratiowas done to assess the latest renal status.
Total patients were divided into two groups; ie Progressors and Non
Progressors. Progressors were defined as those who had doubling of serum
creatinine, development of ESRD or initiation of Renal Replacement Therapy.
Non Progressors had stable serum creatinine or had improvement in serum
creatinine during the followup period.
Apart from clinical, biochemical ,MEST score and immunofluorescence
findings, the associated renal biopsy findings including Cellular or Fibro
cellular crescents, Arteriolar hyaline, Blood vessel thickening, Mesangiolysis,
Glomerular basement thickening and Capillary loop IgA deposit were also
analyzed. Intensity of IgA deposits and co deposits like IgG, IgM, C3 and C1q
in renal tissue was analyzed for its contribution in progression of disease.
Statistical analysis was done to identify significance and correlation of
total MEST score, clinical, biochemical and other histopathological variables in
predicting the renal outcome. Statistical analysis was done using SSPS 15
software. Univariate analysis was done with paired t test and Pearson product
moment correlation coefficient. Multivariate analysis was done with logistic
regression, Cox regression and Kaplan Meier survival analysis.
245 renal biopsies were done between June 2008 and December 2010.
48 patients with biopsy proven IgA nephropathy were enrolled in the study.
Among the 48 patients, 44 patients were followed in our hospital regularly or
irregularly, Rest of the 4 patients lost follow up. We excluded these 4 patients
from our study because of incomplete case records.
Summary of Observation and Results :
Univariate analysis : ‘paired t’ test
Data Non progressor Progressor P value
Total no of patients 25 19
Mean Age 37.12yrs 32.16 yrs
Predominant Age
group
31 -50 yrs 15-30 yrs
Disease status 56.9%(M>F) 43.1%(M (58%)>F)
MAP 109±37 mm Hg 110±51mmHg P=<0.05
NS
Nephrotic Proteinuria 16% 42.1%
Macroscopic
Hematuria
28% 21%
Oliguria 64% 73.6%
Microscopic
Hematuria
100% 100%
BMI 23±3.67 kg/m2 21.19±3.20 kg/m2 P=>0.05
NS
Urine PCR 2.16±1.13 6.06±1.59 P=0.01
Serum Creatinine 1.4mg/dl 2.70mg/dl P=>0.05
NS
Serum Uric acid 5.8±1.65 mg/dl 7.5±1.69 mg/dl P=0.005
Serum TGL 176.24±48.68mg/dl 179.42±34.29mg/dl P=>0.05
NS
Data Non progressor Progressor P value
Creatinine Clearance 59.60±27.86
ml/min
29.29±13.60ml/min P=0.005
Total MEST 2.12±1.01 3.16± 0.76 P=0.005
MEST &
Creatinine<1.0
1.43±0.79 Invalid
MEST&Creat 1.1 to
1.5
2.00± 0.93 2.50± 0.71 P=>0.05
NS
MEST&Creatinine>1.6 2.70± 0.95 3.24±0.75 P=>0.05
NS
IgA intensity 3.48±0.59 3.53±0.80 P=>0.05
NS
Co deposits C3 predominant C3 predominant
Cellular crescents 20% 31.5%
Severe BV thickening 8% 10.5%
Arteriolar hyaline Nil Yes
Summary of Pearson Product Moment Coefficient:
Data Non progressor Progressor
MAP VS MEST
SCORE
p=<0.01 significant P=>0.05 NS
TGL VS MEST
SCORE
P=<0.01 significant P=>0.05 NS
PCR VS MEST
SCORE
P=>0.05 NS P=<0.01 Significant
CR.CL VS MEST
SCORE
P=<0.01 significant P=<0.01 Significant
URIC ACID VS
MEST SCORE
P=>0.05 NS P=>0.0 NS
Summary of Multivariate Analysis:
Logistic regression
analysis
Statistically not
significant
Cox regression analysis Statistically not
significant
Kaplan Meyer survival
analysis
Renal survival with
reference to T score-
significant
Renal survival  with
reference to crescents –
significant
Observations and Results in detail :
245 Renal biopsies were done between June 2008 and December 2010.
IgA nephropathy was found in 44 patients. Incidence of IgA nephropathy in
our study was 16% (n=44). 25 patients were males (56.8%) and 19 patients
were females (47.2%).Male: Female ratio was 1.3:1
Age distribution:
Age group No of patients Percentage
15 -30 yrs 20 45.45%
31 – 50 yrs 23 52.7%
51 – 65 yrs 1 2.27%
Dominant age group of our patient was between 31 to 50yrs (52.7%)
(n=23). 20 patients were in the age group of 15 to 30 yrs, 23 patients were in 31
to 50 yrs age group and one patient was in 51 to 65 yrs age group. Mean age
group of the patient was 35.2 yrs.
Duration of follow up (in months)
Mean period of follow up of the patients was 17.2 months. Follow up
period varied from 4 months to 40 months. Non Progressors were followed for
a mean period of 19.32 months, whereas Progressors were followed up for a
mean period of 14.1 months.  Time to Renal Replacement Therapy in
Progressors was 5.2 months.
Clinical presentation:
Among 44 patients, 5 patients had past history of Hypertension (11.3%)
and on treatment for a period of 2 to 9 yrs. Diabetes mellitus were found in 2
patients (4.5%). Duration of Diabetes Mellitus was 2 years in one patient and 6
years in another patient. Three patients had history of fever during initial
Mean
duration of
follow up
17.2 months
presentation (6.8%); none of the patients had throat pain. Except 2 patients all
presented with pedal edema (n=42) (95.4%).
Age group Progressor (43.1%) Nonprogressor (56.8%)
15-30 12(63.15%) 8
31-50 6 17(68%)
51-65 1 0
Total no of patients 19 25
In 25 out of 44 patients (56.8%) the disease was stable, these patients
were considered as Non Progressors. Predominant age group of Non
Progressor was 31 to 50 years of age (68%). In this group, Systemic
Hypertension and Diabetes Mellitus was found in one patient respectively.
The Disease progressed in 19 patients (43.1%). Progression of disease
was defined as doubling of serum Creatinine, End Stage Renal Disease or
initiation of Renal Replacement Therapy. In Progressors (n=19), past history of
Systemic Hypertension was found in 4 patients and one patient had diabetes
mellitus in addition to SHT. Disease progression was more in younger age
group (15 to 30 years)(12 patients -63.15%) and in Male patients (58%).
11 patients (22%) had macroscopic hematuria. Macroscopic hematuria
was found in 7 (28%) and 4 patients (21%) of Non Progressors and Progressors
respectively. Microscopic hematuria was found in all patients (100%).
4 patients (9.0%) presented with loin pain and 30 patients (68.1%) had
Oliguria. Oliguria was a clinical feature in 16 (64%) and 14 patients (73.6%) of
Non Progressors and Progressors group respectively.
Systemic hypertension was found in all patients at the time of
presentation. The Mean Arterial Pressure of Non Progressors and Progressors
were 109±37 mmHg and 110±51mm Hg respectively. Statistical correlation
with Pearson product moment coefficient was not a significant predictor of
disease progression with reference to mean arterial pressure (p=>0.05).
Nephrotic Proteinuria was present in 12 patients (27.3%). Nephrotic
Proteinuria in Non Progressor and Progressor was 4(16%) and 8(42.1%)
patients respectively.
Nephrotic Proteinuria and Oliguria were the dominant clinical features
in Progressors, but macroscopic hematuria was the predominant feature found
in Non Progressors.
Body Mass Index:
Average Body Mass Index of our patients was 22.21 kg/m2; Body Mass
Index varied from 16 to 30.1 kg/m2. Average Body Mass Index of Non
Progressor group was 22.9 kg/m2 and Average Body Mass Index of Progressor
group was 21.18 kg/m2. Body Mass Index of Non Progressors was found to be
higher than Progressors (22.9±3.67 vs 21.19±3.20 kg/m2).
Statistical analysis of Body Mass Index using `paried t’ test was not
significant in predicting progression of disease (p=>0.05)
Urine spot PCR
Among the 44 patients 28 patients had frothy urine. Urine protein
estimation varies from 2+ to 4+. Mean urine spot Protein Creatinine Ratio was
2.61 gm per gm of creatinine. Urine Spot Protein Creatinine Ratio of Non
Progressor and Progressor was 2.16±1.13 and 6.06±1.59 gm of protein per gm
P=>0.05
of Creatinine respectively. The Mean Urine Spot Protein Creatinine Ratio of
Progressors was higher than Non Progressors.
Statistical analysis of Urine Spot Protein Creatinine Ratio by ‘paired t’
test was significant in predicting the progression of disease (p<0.01). Urine
spot Protein Creatinine Ratio had a statistically significant correlation with
Total MEST score by Pearson product moment coefficient (p<0.01).
Serum creatinine:
Serum creatinine Non Progresor
(no of patients)
Progressor
(no of patients)
<1.0mg/dl 7 0
1.1 to 1.5 mg/dl 8 2
>1.6 mg/dl 10 17
Mean serum Creatinine of patients at the time of admission was
2.08mg/dl.  Average serum Creatinine of Progressor (n=19) was 2.70 mgs/dl.
Among the 19 patients 2 had Serum Creatinine of 1.1.to 1.5 mgs/ dl and rest of
them had Serum Creatinine of >1.6mgs/dl.
Among Non Progressors (n=25), 7 patients had Serum Creatinine of
<1.0 mg/dl, 8 patients had Serum Creatinine of 1.1 to 1.5 mgs/dl and in rest of
the patients (n=10) serum creatinine of >1.6mgs /dl was found at the time of
presentation. Average Serum Creatinineof Non Progressor was 1.4mg/dl.
Statistical analysis using ‘paired t’ test was not significant in predicting
disease progression with reference to Serum Creatinine (p=>0.05). Statistical
analysis using ‘paired t’ test was not significant in predicting the high total
MEST score with reference to Serum Creatinine (p=>0.05).
Serum Creatinine of Progressor:
Serum creatinine of Nonprogressor:
Serum uric acid:
Mean serum uric acid of study population was 6.53 mg/dl. Serum uric
acid of Non Progressor was 5.8±1.65 mg/dl and Progressor was 7.5±1.69
mg/dl.
AVG – 1.4mg/dl
lmg/dl
Statistical analysis using ‘paired t’ test was significantin predicting
disease progression with reference to serum uric acid (p=0.005). In Pearson
product moment coefficient correlation between serum uric acid and total
MEST score was not statistically significant (p=>0.05). Serum uric acid is an
individual predictor of disease progression.
Serum Triglyceride:
Mean serum Triglyceride 176.24 mgs/dl. Average serum Triglyceride of
Progressor 179.5 mgs/dl (n=19). Average serum Triglyceride of Non
Progressor was 176.8 mgs/dl (n=25).  Statistical analysis using paired t test was
not significant in predicting disease progression with reference to serum
triglyceride (p=>0.05).  Statistical analysis using Pearson product moment
coefficient correlation, serum Triglyceride was not significant in predicting
high total MEST score (p=>0.05).
Creatinine clearance:
Mean Creatinine Clearance is 59.60 ml/min, with values varying from
14.3ml/min to 113.5ml/min. Average Creatinine Clearance of Non Progressors
and Progressors was 59.6ml/min and 28.63ml/min respectively.
Glomerular Filtration Rate <30 ml/min was a feature in 4 (9.0%) and 12
(27.5%) patients of Non Progressor and Progressor group respectively.
Statistical analysis using ‘paired t’ test was significant in predicting the
progression of disease with reference to Creatinine Clearance (p=0.005).
Creatinine Clearance had a statistically significant correlation with Total
MEST score in Pearson product moment coefficient correlation (p=0.01).
Creatinine Clearance of Non Progressors:
AVG –59.6ml/
595959.6ML/M
IN
Creatinine Clearance of Progressors:
Average Creatinine Clearance of Progressors was 29.29 ml/min.
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Baseline Creatinine Clearance is a statistically significant individual
predictor of disease Outcome.
MEST scoring:
Total MEST score of cohort varied from 1 to 5, with mean of 2.64. 36%
(9 patients) of Non Progressors had total MEST score of one. Total MEST
score of 3 and 4 was found in 32% and 8 % of patients respectively in Non
Progressors. In Progressors, 57.8 %( n=11) of patients had total MEST score of
score 3 and score of 4 and 5 was found in 21% and 5.2% of patients
respectively.
MEST
score 1 2 3 4 5
Non
Progressor
36%
(n=9)
24%
(n=2)
32%
(n=8)
8%
(n=6) 0
Progressor 0 15.8%(n=3)
57.8%
(n=11)
21%
(n=4)
5.3%
(n=1)
Mean total MEST score of Non Progressors and Progressors was 2.12
and 3.16 respectively. MEST score was higher in patients with Serum
Creatinine >1 .6 mg/dl in both Non Progressor and Progressor group. High
MEST score is a statistically significant individual predictor of Disease
Outcome by paired t test (p=0.005).
MEST score of Non Progressor:
AVG – 2.12
Serum Creatinine and MEST scoring in Non Progressor
MEST scoring of Progressor:
Serum Creatinine and MEST score in Progressor:
Total MEST score of patients with serum creatinine of 1.1 to 1.5 mg/dl
for Non Progressor and Progressor was 2.00± 0.93 and 2.50± 0.71 respectively.
Total MEST score of patients with serum creatinine of >1.6 mg/dl for Non
Progressor and Progressor was 2.70± 0.95 and 3.24±0.75 respectively.
In Paired t test analysis, no statistical significance was found between
Total MEST score and serum creatinine in both non progressors and
progressors (p=>0.05).
Pearson product moment coefficient correlation analysis was done
between Mean Arterial Pressure, Urine spot Protein Creatinine Ratio,
creatinine clearance, Serum Triglyceride and Serum uric acid with Total MEST
score of Progresor and Non Progressor.
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Statistical significant correlation was found between Urine spot Protein
Creatinine Ratio and creatinine clearance with Total MEST score of
Progressors (p=0.01). In Non Progressors, statistical significant correlation was
found between Mean Arterial Pressure, Serum Triglyceride and Creatinine
Clearance with Total MEST score (p=0.01).
Hence high urine spot Protein Creatinine Ratio and low Creatinine
Clearance at the time of presentation predicts severe histopathological lesion
(high Total MEST score) and poor outcome.
Intensity of IgA deposits:
Intensity of IgA deposits varies from 2+ to 4+ in Immunofluorescence
microscopy. 4 + was the intensity of IgA found in both Non Progressors and
Progressors. Statistical analysis using paired t test was not significant in
predicting the disease outcome with reference to IgA intensity (p=>0.05).
Codeposits in immunofluorescence microscopy:
Along with IgA, other immunoglobulins (IgG, IgM, C3, and C1Q)
deposits were also found. Full house pattern (IgG, IgM, IgA) was found in 7
patients (6 – Non Progressors and 1 – Progressors),in all 7 patients C1q and
ANA was negative.
Codeposits in immunofluorescence microscopy – Non Progressors:
C3 in the intensity of 3 + (12 patients) was the predominant co deposit
found in non progressor and along with C3; IgG was also deposited with
intensity of 2+in 5 patients.
Codeposits in immunofluorescence microscopy – Progressors
C3 in the intensity of 4 + was the predominant codeposit in
immunofluorescence microscopy in Progressor (11 patients).
Other Histopathological features:
Cellular crescents, Arteriolar Hyaline and Blood Vessel Thickening
were the other Histopathological features found in light microscopy.
In Non Progressor group, 5patients (20%) had partial Cellular Crescents.
Blood Vessel Thickening was found in 9 patients (36%) with intensity varying
from mild to severe. 2 patients (8%) had severe Blood Vessel thickening. None
of the Non Progressor had Arteriolar Hyaline.
In the Progressor group Partial Cellular crescents was found in 6 patients
(31.5%). 8 patients (42.1%) had Blood Vessel Thickening, among them 2
(10.5%) had Severe Blood Vessel thickening. Arteriolar Hyaline was found in
3 patients (15.7%).
Renal Replacement Therapy modalities in Progressors:
13 out of 19 patients were on Renal Replacement Therapy
(Hemodialysis or Peritoneal Dialysis), 4 patients received live related renal
allograft. Mean period to initiation of Renal Replacement Therapy was 5.2
months after diagnosis.
19 pts
3 PD
13 RRT
10 HD
4 RTX
Multivariate analysis:
Correlation between Clinical, Histopathological and Renal Survival
(outcome) was done using three models of multivariate analysis. ie Logistic
Regression Analysis, Cox Regression Analysis and Kaplan Meier Series
Analysis using SSPS 15 software. Age, Serum creatinine, Urine Spot Protein
Creatinine Ratio, Creatinine Clearance, Individual and Total MEST score,
Cellular Crescents, Arteriolar Hyaline, Blood Vessel Thickening and Time to
Initiation of Renal Replacement Therapy were taken into account. End point
for analysis was fixed as End Stage Renal Disease or Initiation of Renal
Replacement Therapy. In Kaplan Meier series Correlation between T score and
crescents with outcome (ESRD or initiation of Renal Replacement Therapy)
was done.
Logistic Regression Analysis:
Predictability of the test was 68.2% with 95% confidence interval (CI).
Correlation between clinical variables and pathological lesion with outcome
was not statistically significant in predicting renal outcome.
Observed
Predicted
Dialysis PercentageCorrect
Step 0 Dialysis Absent Present
Absent 30 0 100.0
Present 14 0 .0
Overall Percentage 68.2
B S.E. Wald Df Sig. Exp(B)
95.0% C.I.for
EXP(B)
Lower Upper
Step
1(a)
AGE -.007 .058 .015 1 .902 .993 .886 1.113
CREATINE .721 .772 .874 1 .350 2.057 .453 9.338
URINE .401 .443 .823 1 .364 1.494 .628 3.557
CRCL -.015 .059 .066 1 .798 .985 .878 1.105
E .818 1.988 .169 1 .681 2.266 .046 111.638
S -.063 1.849 .001 1 .973 .939 .025 35.155
T -1.142 1.657 .475 1 .491 .319 .012 8.206
CRECENT 1.569 1.821 .742 1 .389 4.800 .135 170.310
AH .856 2.036 .177 1 .674 2.354 .043 127.380
BV .135 .673 .040 1 .841 1.144 .306 4.279
RRT_TIME .966 .395 5.987 1 .014 2.628 1.212 5.699
Constant -4.387 5.202 .711 1 .399 .012
B S.E. Wald Df Sig. Exp(B)
95.0% C.I.for EXP(B)
Lower Upper
Step
1(a)
AGE -.022 .041 .271 1 .603 .979 .902 1.061
CREATIN
E .854 .714 1.430 1 .232 2.349 .579 9.529
URINE .399 .445 .804 1 .370 1.490 .623 3.564
CRCL -.007 .051 .019 1 .889 .993 .899 1.097
CRECEN
T 1.482 1.754 .714 1 .398 4.403 .141 137.013
AH .980 1.961 .250 1 .617 2.664 .057 124.427
BV .146 .677 .046 1 .830 1.157 .307 4.363
RRT_TIM
E .916 .373 6.038 1 .014 2.500 1.204 5.190
MEST_T
OT -.166 .826 .040 1 .841 .847 .168 4.280
Constant -4.809 4.563 1.111 1 .292 .008
Cox Regression Analysis:
Overall predictability of the test was 93.2% with 95% of Confidence
Interval (CI). Correlation between Clinical Variables and Pathological lesion
(MEST) with Outcome was not statistically significant in predicting renal
outcome.
Observed
Predicted
Dialysis PercentageCorrect
Step 1 Dialysis Absent Present
Absent 28 2 93.3
Present 1 13 92.9
Overall Percentage 93.2
B SE Wald df Sig. Exp(B)
95.0% CI for
Exp(B)
Lower Upper
AGE .054 .049 1.178 1 .278 1.055 .958 1.162
SEX -.865 .892 .939 1 .332 .421 .073 2.421
CREATININE .951 .666 2.040 1 .153 2.589 .702 9.550
URINE .616 .411 2.243 1 .134 1.851 .827 4.143
Cr Cl .049 .050 .951 1 .329 1.050 .952 1.158
M . 0(a) .
E 1.370 1.829 .561 1 .454 3.934 .109 141.670
S -.531 1.089 .238 1 .626 .588 .070 4.969
T -.880 2.038 .187 1 .666 .415 .008 22.517
CRESCENT 2.136 1.878 1.294 1 .255 8.464 .213 335.631
AH 1.353 1.805 .562 1 .454 3.868 .113 132.953
BV .494 .524 .888 1 .346 1.639 .586 4.582
B S.E. Wald Df Sig.
Exp
(B)
95.0% C.I.for
EXP(B)
Lower Upper
Step
1(a)
AGE
-.022 .041 .271 1 .603 .979 .902 1.061
CREATININE .854 .714 1.430 1 .232 2.349 .579 9.529
URINE .399 .445 .804 1 .370 1.490 .623 3.564
Cr Cl -.007 .051 .019 1 .889 .993 .899 1.097
CRESCENT 1.482 1.754 .714 1 .398 4.403 .141 137.013
AH .980 1.961 .250 1 .617 2.664 .057 124.427
BV .146 .677 .046 1 .830 1.157 .307 4.363
RRT_TIME .916 .373 6.038 1 .014 2.500 1.204 5.190
MEST_TOT -.166 .826 .040 1 .841 .847 .168 4.280
Constant -4.809 4.563 1.111 1 .292 .008
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Kaplan Meier analysis:
Predictability of the test was 68.18%.  Correlation between T (Tubular)
score and Cellular Crescents with Renal Outcome was statistically significant.
These pathological lesions were Independent predictors of Renal Survival in
Kaplan Meyer analysis. Clinical and other pathological features (MES – score,
Arteriolar Hyaline and Blood vessel thickening) were not statistically
significant.
Survival Analysis for RRT_TIME RRT in months
Total
Events
Number
Censored
Number
Censored
Percent
T 0 12 0 12 100.00
T 1 30 14 16 53.33
T 2 2 0 2 100.00
Overall 44 14 30 68.18
Test Statistics for Equality of Survival Distributions for T
Statistic df Significance
Log Rank .96 2 .6202
Breslow .96 2 .6202
Tarone-Ware .96 2 .6202
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Kaplan meier analysis for crescents:
Survival Analysis for RRT_TIME RRT in months
Total Events Number
Censored
Number
Censored
Percent
Crescent Absent 33 10 23 69.70
Crescent Present 11 4 7 63.64
Overall 44 14 30 68.18
Test Statistics for Equality of Survival Distributions for CRESCENT
Statistic df Significance
Log Rank 7.05 1 .0079
Breslow 2.65 1 .1035
Tarone-Ware 4.68 1 .0306
Discussion:
In our study, the incidence of IgA nephropathy is 16%. This result was
comparable with a Retrospective study from Kerala, which showed an
increasing trend of IgA nephropathy (15.52%) 18. We also compared our study
results with the previous reports, an incidence of 4.2% was reported from
Tamil Nadu11 in 1987, an incidence of 7.24% from New Delhi12 in 1992, and
an incidence of 10.37% from the Union Territory of Chandigarh13 in 1995, and
found an increasing trend of IgA nephropathy.
Radford MG etal14 reported that, Primary IgA nephropathy occurs at any
age, most commonly with clinical onset in the second and third decades of life.
In discordant with this study report, our patients were predominantly belonging
to 4th and 5thdecade and none of the patients had age of less than 15 years.
In similarity with the Ibels LS et al15study, males were predominant in
our cohort. Hogg et al64 (1994) observed 15 percent of the patients developed
end stage renal disease in a mean follow up period of 4 yrs. In discordance with
this study, 43.1% of our patients developed end stage renal disease in a mean
follow up period of 17.2 months. Disease progressed more in younger age
group between 15 to 30 years of age.
Mark Hass et al50 sub classified IgA Nephropathy into subclass
I(Minimal or No Mesangial Hypercellularity) subclass II (Focal and Segmental
Glomerular Sclerosis without Mesangial Cellularity) subclass III(Focal
Proliferative Glomerulonephrits) subclass IV (Diffuse Proliferative
Glomerulonephrits) and sub class V (>40% Global Glomerular Sclerosis and >
40% Tubular Atrophy).
Mark’s clinicopathological analysis revealed that prognosis was better
in sub class I and II,  prognosis was intermediate in sub class III and  prognosis
was poor in sub class IV and V and additionally poor prognosis was found in
the presence of Cellular Crescents, Fibro Cellular Crescents and Tubular
Atrophy of > 20 %.  Clinical findings like high Serum Creatinine, Nephrotic
Proteinuria and Hypertension were also markers of poor prognosis. Mark et
al50found that patients with Gross Hematuria had good prognosis. Apart from
proteinuria and hypertension all other variables were not statistically
significant.
In our study clinical factors like Proteinuria (Non Progressor and
Progressor 2.16±1.13 and 6.06±1.59 mg per gm of creatinine p= 0.01), Serum
Uric acid (Non Progressors and Progressor 5.8±1.65 mg/dl 7.5±1.69 mg/dl p=
0.005) and Creatinine Clearance (Non Progresors and Progressors 59.60±27.86
28.63±13.60 ml/min; p=0.005) were independent predictors of the outcome of
the disease. When these findings were compared with the Clinicopathological
correlation done by Hass, they were found to be concordant. Univariate
Analysis with ‘paired t’ test confirms the statistical significance of these
clinical variables.
In our study in addition to clinical factors, histological features like
Cellular Crescents (20% Non Progressor vs 31.5% Progressor), Severe Blood
Vessel Thickening (8 % Non Progressor vs 10.5% Progressor) and Arteriolar
Hyaline were also associated with poor outcome (ESRD or initiation of RRT or
doubling of serum creatinine).
In a large scale cohort study by Masashi Goto etal65,a scoring system
was proposed to estimate the ESRD risk  within 10 yrs of onset of disease,
using eight variables; these variables were 1.Male sex 2.Age less than 30 years
3.The presence of family history of chronic renal failure and chronic
glomerulonephritis 4. Hypertension 5. Proteinuria and Mild Hematuria
6.Hypoalbuminaemia 7.LowGFR and 8.High Histological grade. This
prognostic score accurately classified the patients by ESRD risk. Patients with
estimated scores of 0–4.9, 5.0–19.9, 20.0–49.9 and 50.0–100% had an observed
incidence of 1.7, 8.3, 36.7 and 85.5%, of progression to ESRD respectively.
This prognostic score quantitatively estimates the ESRD risk during 10 year
follow up and this serves as a useful prognostic tool in clinical practice.
In our study male sex, age <30 years, Nephrotic range Proteinuria, low
Creatinine Clearance and Histological severity in the form of Tubular atrophy,
Crescents, Severe Blood Vessel thickening and Arteriolar Hyaline were the
variables associated with poor outcome (ERSD, doubling of serum creatinine
or initiation of Renal Replacement Therapy). These results were in
concordance with the results of a large scale cohort study by Masashi Goto65.
In a single Center study of 146 patients done by Michael Walsh et al 66,
three Histopathological parameters 1.Fibrosis of Interstitial area>25%
2.Sclerosis of Glomerular area> 40% and 3.Prescence of Crescents were found
to be independent predictors of composite end point (doubling of serum
creatinine, End Stage Renal Disease and Death).  Clinical variables like
significant Proteinuria (80%), high Serum Creatinine (38%) and blood pressure
of >130/90 mm Hg (55%) were also predictors of poor prognosis.
Similarly in our study, patients with Nephrotic range Proteinuria had a
statistically significant correlation with poor outcome. In addition, low
Creatinine Clearance and high Serum Uric acid levels were also independent
predictors of poor outcome.In discordant to this single center study by Michael
Walsh et al66, serum Creatinine was not a statistically significant predictor of
disease outcome.
Comparing the Histopathological variables in our study, Tubular
atrophy (T score>50 %) and Cellular crescents were independent predictors of
disease progression (Using Kaplan Meier survival analysis). These results were
similar to the study done by Michael Walsh el al.
A Working Group of the International IgA Nephropathy Network and
the Renal Pathology Society introduced the Oxford MEST scoring system by
analysis of 265 renal biopsy samples 60. This analysis consists of four variables,
Mesangial hypercellularity, Segmental sclerosis, Endocapillary proliferation
and Tubular atrophy/ interstitial fibrosis.
In their series,15% of the patients were <18 yrs of age, Median follow
up period was 5 yrs. Strong association was found between initial eGFR, MAP,
proteinuria and poor renal outcome.  Follow up Mean Arterial Pressure and
proteinuria were also predictors of poor renal outcome. High MEST score were
significantly associated with proteinuria. Segmental sclerosis, tubular atrophy
and arterial disease were strongly associated with low eGFR and initial high
MAP. Poor Renal outcome was significantly associated with mesangial
hypercellularity, segmental sclerosis and tubular atrophy. These distinct
pathological variables had prognostic value independent of all clinical and
laboratory parameters. Endocapillary and extracapillary scores were not
statistically significant in predicting adverse renal outcome. Immunosuppresive
drugs were prescribed according to endocapillary or extracapliiary scores.
Oxford IgA Nephropathy classification was validated in North
American cohort by Andrew M. Herzenberget al62, using an independent cohort
of 187 adults and children. Their clinical characters were comparable in age,
eGFR, proteinuria and mean arterial pressure at time of biopsy with Oxford
derivation cohort.  Three of the four pathological variables as in Oxford cohort
predicted the rapid decline in renal function.  When compared to the Oxford
cohort, North American cohort received more immununosuppresive drugs and
anti hypertensives.
In similarity with OXFORD MEST scoring system and its North
American cohort results, Clinical variables like Creatinine Clearance and
Nephrotic range Proteinuria were concordant  in predicting therenal outcome.(
Univariate analysis -paired t test) (p=0.005). Mean Arterial pressure was not a
predictor of disease outcome in our study.
Correlation between Total MEST score and Renal outcome
(ESRD/RRT) was statistically significant in univariate analysis (p=0.005). But
Correlation between individual and total MEST score with renal outcome was
not statistically significant in multivariate analysis (Logistic regression and
Cox regression). T scores (Tubular) and crescents were found to be individual
predictors of renal survival in Kaplan Meier survival analysis. Results of this
multivariate analysis were discordant with OXFORD MEST scoring system
and its North American validation.
As strict immunosuppressive protocol was not followed in our study,
our treatment modalities are not comparable with other studies. All the 44
patients received Angiotensin Converting Enzyme inhibitors and Statins. Inj
Methyl Prednisolone and oral Prednisolone was prescribed for patients with
crescents for varied periods.
Conclusion:
In our study,
1. High Total MEST score at the time of presentation is an individual
predictor of Disease Outcome.
2 High MEST score predicts Low baseline Creatinine clearance and
Nephrotic Proteinuria.
3. Low baseline Creatinine Clearance, Nephrotic proteinuria and Serum
Uric acid are individual predictors of disease progression.
4. Tubular atrophy (T score in MEST) and Partial Crescents individually
predicts the Renal Survival.
5. MEST score is neither superior nor inferior in predicting the Renal
Outcome when compared to Creatinine Clearance and Nephrotic
proteinuria.
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